On 16 January 2018, Scope Fluidics S.A. signed a letter of intent with one of the biggest Polish networks of medical labs – ALAB Laboratories. The aim of cooperation is to streamline the process of industrialization and market validation of our key projects – PCR|ONE and Bacteromic. In addition, our partner will participate in validation of PCR|ONE system with a view to confirming its functionality and market advantage.
Required R&D works on the PCR|ONE system, include e.g. a series of diagnostic tests in third-party laboratories. ALAB Laboratories will conduct the market validation of the system, especially during the initial period of its official market availability. With its 70 laboratories and 50 million of tests conducted yearly, ALAB Laboratories is one of the biggest Polish networks of medical labs. It is also a member of Limbach group of laboratories.
– By signing a letter of intent with ALAB Laboratories, we have confirmed our readiness to begin cooperation, testing, approval and implementation of the PCR|ONE system in the Polish market. It is a great honor for us that the process of market validation will be conducted by a large company which is well-known and appreciated on the medical market. This close cooperation with one of the biggest Polish networks of laboratories is meant to support the development of modern medical diagnostics. Moreover, the letter of intent is a significant step forward in our negotiations with potential partners, says Marcin Izydorzak, a co-founder and Member of the Board of Scope Fluidics S.A.
At the beginning of this year, our company began the process of PCR|ONE system industrialization, i.e. preparation of the industrial production technology. The first step is to choose partners who will provide assistance in the optimization of production processes and conclude agreements with them. ALAB Laboratories declared its readiness to cooperate with us on validation of the PCR|ONE system. Besides the PCR|ONE system for ultra-rapid infection detection, ALAB Laboratories is also interested in a younger system created by the Scope Fluidics group, namely Bacteromic, for comprehensive antibiotics susceptibility testing (AST), and would like to consult the details of its functionality.
